• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Infinity Pharmaceuticals Announces Termination of Merger Agreement with MEI Pharma

    7/24/23 8:30:00 AM ET
    $INFI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $INFI alert in real time by email

    Eganelisib Remains Primary Value Driver for Infinity

    Infinity to Explore Strategic Alternatives to Maximize Value for Stockholders

    Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) ("Infinity"), a clinical-stage biotechnology company developing eganelisib, a potential first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, announced that it has terminated its previously announced merger agreement providing for the merger with MEI Pharma, Inc. ("MEI").

    At a special meeting of MEI stockholders on July 23, 2023, MEI did not obtain MEI stockholder approval for the merger with Infinity, nor could MEI obtain approval for an adjournment of the special meeting. In the process of attempting to obtain approval for the merger, which the MEI board supported based on the value creation potential of the combined companies with eganelisib as the lead asset, MEI was forced to contend with an unsolicited public proposal to acquire MEI by certain activist stockholders who launched a public campaign to buy MEI at a significant discount to its cash on hand.

    Infinity has continued to prepare for the initiation of a planned global Phase 2 clinical trial evaluating eganelisib in head and neck squamous cell carcinoma, and, following FDA feedback, the final protocol has been submitted to the FDA. Based on the strength of the eganelisib data generated across several tumor types to date, Infinity's board of directors continues to believe in the value of eganelisib and will explore strategic alternatives intended to realize this potential value. Infinity's board believes that eganelisib offers a near-term value creation opportunity and would be attractive to potential acquirers and intends to engage one or more strategic advisors to assist in the process. In an effort to conserve resources and preserve value for stockholders during this process, the company's board and management team expect to undertake a series of cost saving measures.

    Infinity provided a conditional notice of termination to MEI indicating that Infinity was terminating the merger agreement if MEI did not obtain stockholder approval of the issuance of MEI common stock in connection with the merger. As a result of the termination of the merger agreement, we believe Infinity is entitled to reimbursement of certain expenses and fees of $1,000,000 from MEI in accordance with the terms of the merger agreement. Infinity has the potential to receive an additional $4,000,000 termination fee from MEI under certain circumstances outlined in the joint proxy statement/prospectus relating to the merger.

    About Infinity Pharmaceuticals

    Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) is a clinical-stage biotechnology company developing eganelisib (IPI-549), a potential first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic which is designed to address a fundamental biologic mechanism of immune suppression in cancer in multiple clinical studies. For more information on Infinity, please refer to Infinity's website at www.infi.com.

    Cautionary Statement Regarding Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements include the potential of eganelisib; the company's plans to explore strategic alternatives; and the company's ability to execute on its strategic plans. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from the company's current expectations. For example, substantial doubt exists about the company's ability to continue as a going concern. In addition, there can be no guarantee that eganelisib will successfully complete necessary preclinical and clinical development phases, that the company will be successful in establishing a strategic partnership to further the development of eganelisib or that any positive developments in Infinity's product portfolio will result in stock price appreciation. Management's expectations and, therefore, any forward-looking statements in this press release could also be affected by risks and uncertainties relating to a number of other factors, including the following: Infinity's ability to continue as a going concern; Infinity's ability to successfully identify one or more strategic opportunities for eganelisib; the cost, timing and results of clinical trials and other development activities that may be delayed or disrupted by the COVID-19 pandemic or otherwise; the content and timing of decisions made by the FDA and other regulatory authorities; Infinity's ability to obtain and maintain requisite regulatory approvals; unplanned cash requirements and expenditures; development of agents by Infinity's competitors for diseases in which Infinity is currently developing or intends to develop eganelisib; and Infinity's ability to obtain, maintain and enforce patent and other intellectual property protection for eganelisib. These and other risks which may impact management's expectations are described in greater detail under the caption "Risk Factors" included in Infinity's annual report and quarterly reports filed with the Securities and Exchange Commission (SEC), and in other filings that Infinity makes with the SEC, available through the company's website at www.infi.com. Any forward-looking statements contained in this press release speak only as of the date hereof, and Infinity does not undertake and expressly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

    This press release contains hyperlinks to information that is not deemed to be incorporated by reference.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20230723820750/en/

    Get the next $INFI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $INFI

    DatePrice TargetRatingAnalyst
    10/18/2021$9.00Buy
    HC Wainwright & Co.
    8/2/2021$6.00Neutral → Overweight
    JP Morgan
    7/28/2021$4.00 → $14.00Equal-Weight → Overweight
    Wells Fargo
    7/7/2021$7.00Buy
    B. Riley Securities
    More analyst ratings

    $INFI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Infinity Pharmaceuticals Announces Value Preservation and Maximization Plan

      Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) ("Infinity" or the "Company"), a clinical-stage biotechnology company developing eganelisib, a potential first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, today announced a series of actions designed to reduce the Company's burn rate and enhance our ability to maximize value of eganelisib, following the termination of its previously announced merger agreement with MEI Pharma, Inc. The Company continues to believe, based on the data generated to date, that eganelisib offers a near-term value creation opportunity that would be attractive to potential third-party acquirers. Infinity has advanced eganelisib toward the init

      7/25/23 4:05:00 PM ET
      $INFI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Infinity Pharmaceuticals Announces Termination of Merger Agreement with MEI Pharma

      Eganelisib Remains Primary Value Driver for Infinity Infinity to Explore Strategic Alternatives to Maximize Value for Stockholders Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) ("Infinity"), a clinical-stage biotechnology company developing eganelisib, a potential first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, announced that it has terminated its previously announced merger agreement providing for the merger with MEI Pharma, Inc. ("MEI"). At a special meeting of MEI stockholders on July 23, 2023, MEI did not obtain MEI stockholder approval for the merger with Infinity, nor could MEI obtain approval for an adjournment of the special meeting. In the process o

      7/24/23 8:30:00 AM ET
      $INFI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MEI Pharma Reminds Shareholders to Vote Today FOR the Infinity Transaction

      MEI Pharma, Inc. (NASDAQ:MEIP) (the "Company") today reminded shareholders to vote FOR the pending transaction with Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) ("Infinity") in connection with the Company's special meeting on July 23, 2023. MEI issued the following statement: Our shareholders have the opportunity to shape the future of their MEI investment. By voting FOR the Infinity transaction today, you have the opportunity to participate in the upside potential of a combined company with: a diversified therapeutic pipeline; a team that brings clinical development and regulatory expertise; and the capabilities and resources to develop new oncology therapeutics for the benefi

      7/19/23 8:00:00 AM ET
      $INFI
      $MEIP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $INFI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Infinity Pharmaceuticals Inc. (Amendment)

      SC 13G/A - INFINITY PHARMACEUTICALS, INC. (0001113148) (Subject)

      2/14/23 3:59:19 PM ET
      $INFI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Infinity Pharmaceuticals Inc. (Amendment)

      SC 13G/A - INFINITY PHARMACEUTICALS, INC. (0001113148) (Subject)

      2/9/23 11:22:21 AM ET
      $INFI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Infinity Pharmaceuticals Inc. (Amendment)

      SC 13G/A - INFINITY PHARMACEUTICALS, INC. (0001113148) (Subject)

      2/14/22 2:01:09 PM ET
      $INFI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $INFI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • HC Wainwright & Co. initiated coverage on Infinity Pharmaceuticals with a new price target

      HC Wainwright & Co. initiated coverage of Infinity Pharmaceuticals with a rating of Buy and set a new price target of $9.00

      10/18/21 6:27:01 AM ET
      $INFI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Infinity Pharmaceuticals upgraded by JP Morgan with a new price target

      JP Morgan upgraded Infinity Pharmaceuticals from Neutral to Overweight and set a new price target of $6.00

      8/2/21 5:42:58 AM ET
      $INFI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Infinity Pharmaceuticals upgraded by Wells Fargo with a new price target

      Wells Fargo upgraded Infinity Pharmaceuticals from Equal-Weight to Overweight and set a new price target of $14.00 from $4.00 previously

      7/28/21 5:37:19 AM ET
      $INFI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $INFI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Perkins Adelene Q converted options into 768,133 shares and sold $28,714 worth of shares (410,196 units at $0.07), increasing direct ownership by 44% to 1,175,291 units

      4 - INFINITY PHARMACEUTICALS, INC. (0001113148) (Issuer)

      9/12/23 6:20:24 PM ET
      $INFI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Peluso Stephane converted options into 50,000 shares, increasing direct ownership by 1,711% to 37,052 units to cover taxes

      4 - INFINITY PHARMACEUTICALS, INC. (0001113148) (Issuer)

      8/4/22 6:26:16 PM ET
      $INFI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Evnin Anthony B was granted 46,378 shares, increasing direct ownership by 27% to 215,403 units

      4 - INFINITY PHARMACEUTICALS, INC. (0001113148) (Issuer)

      6/16/22 9:29:24 PM ET
      $INFI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $INFI
    Financials

    Live finance-specific insights

    See more
    • MEI Pharma and Infinity Pharmaceuticals Announce Definitive Merger Agreement to Advance Three Promising Clinical Oncology Candidates

      Combination will create a company with a diverse product development pipeline led by a planned new global Phase 2 clinical trial evaluating eganelisib in head and neck squamous cell carcinoma (HNSCC) Projected ~$100M cash balance of combined company expected to fund operations through mid-2025 and to clinical data over the next 12 to 24 months Companies to host conference call and webcast today at 8:00 a.m. ET MEI Pharma, Inc. (NASDAQ:MEIP) ("MEI"), a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, and Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) ("Infinity"), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno

      2/23/23 7:00:00 AM ET
      $INFI
      $MEIP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Infinity Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update

      – MARIO-3 Update in Patients with 1L TNBC showing 52% increase in one-year progression free survival rate in ITT patient population compared to Impassion130 benchmark – – Business development discussions advancing with goal of announcing a partnership in Q1 2023 – – Cash runway into 2024 with $47.2 million in cash and cash equivalents at end of Q3 2022– – Investor conference call to be held today at 8:30 AM ET – Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) ("Infinity" or the "Company"), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, today announced its third quarter 2022 financial results, provi

      11/14/22 7:07:00 AM ET
      $INFI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Infinity Pharmaceuticals Announces the Date of Its Third Quarter 2022 Financial Results Conference Call and Webcast

      Infinity Pharmaceuticals, Inc. (NASDAQ:INFI), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, will host a conference call on Monday, November 14, 2022, at 8:30 AM ET to report its financial results for the third quarter of 2022. To access the conference call, please register at https://register.vevent.com/register/BId44f86e6a2af42faadbb2844131346a8. Upon registering, each participant will be provided with call details and access codes. All participants are encouraged to join 10 minutes prior to the start time. A live webcast of the conference call can be accessed from the Events & Presentations page

      11/7/22 8:25:00 AM ET
      $INFI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $INFI
    SEC Filings

    See more
    • Infinity Pharmaceuticals Inc. filed SEC Form 8-K: Bankruptcy or Receivership, Leadership Update

      8-K - INFINITY PHARMACEUTICALS, INC. (0001113148) (Filer)

      9/29/23 4:04:01 PM ET
      $INFI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Infinity Pharmaceuticals Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      8-K - INFINITY PHARMACEUTICALS, INC. (0001113148) (Filer)

      9/13/23 8:11:15 AM ET
      $INFI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Infinity Pharmaceuticals Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      8-K - INFINITY PHARMACEUTICALS, INC. (0001113148) (Filer)

      9/11/23 4:09:04 PM ET
      $INFI
      Biotechnology: Pharmaceutical Preparations
      Health Care